Targeting SRSF10 might inhibit M2 macrophage polarization and potentiate anti‐PD‐1 therapy in hepatocellular carcinoma
Cancer Communications · 2024-11 · 44 (11) · 1231-1260
DOI: 10.1002/cac2.12607 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Communications, online erschienen am 02.09.2024. Verfasst von Jialiang Cai und 14 weiteren Autor:innen. Beteiligte Einrichtung: Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, P. R. China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Serine-Arginine Splicing Factors, Liver Neoplasms, Macrophages. Die Arbeit wurde bisher 202-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Leading Project of the Science and Technology Committee of Shanghai Municipality, Project of Shanghai Municipal Health Commission.
Abstract (Originalsprache)
Background
The efficacy of immune checkpoint blockade therapy in patients with hepatocellular carcinoma (HCC) remains poor. Although serine‐ and arginine‐rich splicing factor (SRSF) family members play crucial roles in tumors, their impact on tumor immunology remains unclear. This study aimed to elucidate the role of SRSF10 in HCC immunotherapy.
Methods
To identify the key genes associated with immunotherapy resistance, we conducted single‐nuclear RNA sequencing, multiplex immunofluorescence, and The Cancer Genome Atlas and Gene Expression Omnibus database analyses. We investigated the biological functions of SRSF10 in immune evasion using in vitro co‐culture systems, flow cytometry, various tumor‐bearing mouse models, and patient‐derived organotypic tumor spheroids.
Results
SRSF10 was upregulated in various tumors and associated with poor prognosis. Moreover, SRSF10 positively regulated lactate production, and SRSF10/glycolysis/ histone H3 lysine 18 lactylation (H3K18la) formed a positive feedback loop in tumor cells. Increased lactate levels promoted M2 macrophage polarization, thereby inhibiting CD8 + T cell activity. Mechanistically, SRSF10 interacted with the 3′‐untranslated region of MYB , enhancing MYB RNA stability, and subsequently upregulating key glycolysis‐related enzymes including glucose transporter 1 ( GLUT1 ), hexokinase 1 ( HK1 ), lactate dehydrogenase A ( LDHA ), resulting in elevated intracellular and extracellular lactate levels. Lactate accumulation induced histone lactylation, which further upregulated SRSF10 expression. Additionally, lactate produced by tumors induced lactylation of the histone H3K18la site upon transport into macrophages, thereby activating transcription and enhancing pro‐tumor macrophage activity. M2 macrophages, in turn, inhibited the enrichment of CD8 + T cells and the proportion of interferon‐γ + CD8 + T cells in the tumor microenvironment (TME), thus creating an immunosuppressive TME. Clinically, SRSF10 could serve as a biomarker for assessing immunotherapy resistance in various solid tumors. Pharmacological targeting of SRSF10 with a selective inhibitor 1C8 enhanced the efficacy of programmed cell death 1 (PD‐1) monoclonal antibodies (mAbs) in both murine and human preclinical models.
Conclusions
The SRSF10/MYB/glycolysis/lactate axis is critical for triggering immune evasion and anti‐PD‐1 resistance. Inhibiting SRSF10 by 1C8 may overcome anti‐PD‐1 tolerance in HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, P. R. China.
- State Key Laboratory of Genetic Engineering, Fudan University, Shanghai, P. R. China.
- Key Laboratory of Carcinogenesis and Cancer Invasion, Fudan University, Ministry of Education, Shanghai, P. R. China.
- Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, P. R. China.
- Shanghai Institute of Liver Disease, Shanghai, P. R. China.
- Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, P. R. China.
ORCID-Profile: Lina Song, Feng Zhang, Guiqi Zhu, Zhi Dai
Förderung
- National Natural Science Foundation of China
- Leading Project of the Science and Technology Committee of Shanghai Municipality
- Project of Shanghai Municipal Health Commission
Zitieren
APA
Cai, J., Song, L., Zhang, F., Wu, S., Zhu, G., Zhang, P., Chen, S., Du, J., Wang, B., Cai, Y., Yang, Y., Wan, J., Zhou, J., Fan, J., & Dai, Z. (2024). Targeting SRSF10 might inhibit M2 macrophage polarization and potentiate anti‐PD‐1 therapy in hepatocellular carcinoma. Cancer Communications, 44(11), 1231-1260. https://doi.org/10.1002/cac2.12607
Vancouver
Cai J, Song L, Zhang F, Wu S, Zhu G, Zhang P, et al. Targeting SRSF10 might inhibit M2 macrophage polarization and potentiate anti‐PD‐1 therapy in hepatocellular carcinoma. Cancer Communications. 2024;44(11):1231-1260. doi:10.1002/cac2.12607
BibTeX
@article{Cai2024,
author = {Cai, Jialiang and Song, Lina and Zhang, Feng and Wu, Suiyi and Zhu, Guiqi and Zhang, Peiling and Chen, Shiping and Du, Junxian and Wang, Biao and Cai, Yufan and Yang, Yi and Wan, Jinglei and Zhou, Jian and Fan, Jia and Dai, Zhi},
title = {Targeting SRSF10 might inhibit M2 macrophage polarization and potentiate anti‐PD‐1 therapy in hepatocellular carcinoma},
journal = {Cancer Communications},
year = {2024},
volume = {44},
number = {11},
pages = {1231--1260},
doi = {10.1002/cac2.12607}
}
EUVIMED